Immunity Unveiled: a Translational Network for Tackling Parkinson's Disease – Immuparknet
| dc.contributor.author | Gugu, M. | |
| dc.contributor.author | Acharya, S. | |
| dc.contributor.author | Pira, D. | |
| dc.contributor.author | Poletti, S. | |
| dc.contributor.author | di Flora, A. | |
| dc.contributor.author | Saksida, T. | |
| dc.contributor.author | Figueira, I. | |
| dc.date.accessioned | 2025-02-25T19:32:13Z | |
| dc.date.available | 2025-02-25T19:32:13Z | |
| dc.date.issued | 2025 | |
| dc.description.abstract | Parkinson’s disease (PD) affects more than one million people in the EU. It currently has no definitive cure, meaning that patients rely only on symptomatic treatments, which themselves are burdened by side effects. The need for advancements in both knowledge and available treatments is thus strongly felt by patients, caregivers, and health operators. This unmet need sparked the idea of orchestrating a collaborative effort via a common network – IMMUPARKNET (The role of IMMUnity in tackling PARKinson’s disease through a Translational NETwork). The IMMUPARKNET COST Action focuses on challenges in PD and its related crosstalk with immune response. Although widely recognized, the role of immunity in the onset and development of PD is still unclear. The main goal of IMMUPARKNET is to fill this knowledge gap by establishing an innovative, interdisciplinary research network and fostering exchanges of expertise among specialists from different countries and institutions. As we gather scientists and clinicians who study immunity in PD and related fields, IMMUPARKNET will establish the first nucleus of a multidisciplinary ecosystem that aims to harmonize efforts and approaches, both in research and clinical practice, to boost the development of ground-breaking treatments for PD. Through meetings, training schools, webinars, position papers, and review manuscripts, IMMUPARKNET will lead fruitful exchanges of know-how among experts in the field. The IMMUPARKNET structure revolves around 5 working groups, with a total of 157 active members from 34 different countries. Of these active members, 58.5% are young researchers, while 67.5% come from Inclusiveness Target Countries (ITC - less research-intensive COST Members; https://www.cost.eu/about/members/). IMMUPARKNET output will facilitate the improved sharing and development of research resources, straightening the road to novel treatments and identifying where existing ones can be repurposed, all, ultimately and hopefully, finding a cure for PD. Copyright: © 2025 Gugu M et al. | en_US |
| dc.identifier.doi | 10.12688/openreseurope.17547.2 | |
| dc.identifier.issn | 2732-5121 | |
| dc.identifier.scopus | 2-s2.0-85217444470 | |
| dc.identifier.uri | https://doi.org/10.12688/openreseurope.17547.2 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14365/5950 | |
| dc.language.iso | en | en_US |
| dc.publisher | F1000 Research Ltd | en_US |
| dc.relation.ispartof | Open Research Europe | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.subject | Immune Response | en_US |
| dc.subject | Network | en_US |
| dc.subject | Parkinson'S Disease | en_US |
| dc.title | Immunity Unveiled: a Translational Network for Tackling Parkinson's Disease – Immuparknet | en_US |
| dc.type | Letter | en_US |
| dspace.entity.type | Publication | |
| gdc.author.scopusid | 57425554200 | |
| gdc.author.scopusid | 57224739314 | |
| gdc.author.scopusid | 58421235000 | |
| gdc.author.scopusid | 59550938400 | |
| gdc.author.scopusid | 58661476000 | |
| gdc.author.scopusid | 46061288700 | |
| gdc.author.scopusid | 6701468226 | |
| gdc.bip.impulseclass | C5 | |
| gdc.bip.influenceclass | C5 | |
| gdc.bip.popularityclass | C5 | |
| gdc.coar.access | metadata only access | |
| gdc.coar.type | text::letter | |
| gdc.collaboration.industrial | false | |
| gdc.description.department | İzmir Ekonomi Üniversitesi | en_US |
| gdc.description.departmenttemp | Gugu M., Preclinical Department, Faculty of Technical Medical Sciences, University of Elbasan “Aleksandër Xhuvani”, Elbasan, Albania; Acharya S., Luxembourg and Faculty of Science, Technology and Medicine, University of Luxembourg, Luxembourg, Luxembourg, Cardiovascular Research Unit, Department of Precision Health, Luxembourg Institute of Health, Luxembourg, Luxembourg; Pira D., Faculty of Medicine, Izmir University of Economics, Izmir, Türkiye; Poletti S., Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy; di Flora A., Center for Research in Medical Pharmacology, School of Medicine, University of Insubria, Lombardy, Varese, Italy; Saksida T., Institute for Biological Research "Siniša Stanković", National Institute of Republic of Serbia, University of Belgrade, Belgrade, Serbia; Pilipenko V., Department of Pharmacology, Faculty of Medicine, University of Latvia, Riga, Riga, Latvia; Romero-Ramos M., Danish Research Institute of Translational Neuroscience – DANDRITE, Department of Biomedicine, Aarhus University, Central Denmark Region, Aarhus, Denmark; Marino F., Center for Research in Medical Pharmacology, School of Medicine, University of Insubria, Lombardy, Varese, Italy; Muñoz Delgado L., Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC, Universidad de Sevilla, Andalusia, Seville, Spain; Nikolovski N., Institute for Biological Research "Siniša Stanković", National Institute of Republic of Serbia, University of Belgrade, Belgrade, Serbia; Gursoy Ozdemir Y., Department of Neurology, School of Medicine, Koç University, İstanbul, Istanbul, Türkiye; Lawson D., University of Eastern Piedmont, Novara, Italy; Comi C., Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy, S. Andrea Hospital, Vercelli, Italy; Figueira I., NOVA Medica School, Faculdade de Ciências Médicas (NMS|FCM), Universidade Nova de Lisboa, Lisbon, Lisbon, Portugal | en_US |
| gdc.description.publicationcategory | Diğer | en_US |
| gdc.description.scopusquality | Q2 | |
| gdc.description.volume | 4 | en_US |
| gdc.description.wosquality | N/A | |
| gdc.identifier.openalex | W4406756540 | |
| gdc.index.type | Scopus | |
| gdc.oaire.accesstype | HYBRID | |
| gdc.oaire.diamondjournal | false | |
| gdc.oaire.impulse | 1.0 | |
| gdc.oaire.influence | 2.4986813E-9 | |
| gdc.oaire.isgreen | true | |
| gdc.oaire.keywords | Parkinson's disease | |
| gdc.oaire.keywords | network | |
| gdc.oaire.keywords | Parkinson's disease;immune response;network | |
| gdc.oaire.keywords | 610 | |
| gdc.oaire.keywords | Open Letter | |
| gdc.oaire.keywords | immune response | |
| gdc.oaire.keywords | General | |
| gdc.oaire.keywords | Parkinson's disease; immune response; network | |
| gdc.oaire.popularity | 3.110569E-9 | |
| gdc.oaire.publicfunded | false | |
| gdc.openalex.collaboration | International | |
| gdc.openalex.fwci | 1.5123 | |
| gdc.openalex.normalizedpercentile | 0.77 | |
| gdc.openalex.toppercent | TOP 10% | |
| gdc.opencitations.count | 0 | |
| gdc.plumx.newscount | 1 | |
| gdc.plumx.scopuscites | 1 | |
| gdc.scopus.citedcount | 1 | |
| relation.isOrgUnitOfPublication | e9e77e3e-bc94-40a7-9b24-b807b2cd0319 | |
| relation.isOrgUnitOfPublication.latestForDiscovery | e9e77e3e-bc94-40a7-9b24-b807b2cd0319 |
